Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 May;15(5):523-9.
doi: 10.1089/acm.2008.0402.

Dietary supplement S-adenosyl-L-methionine (AdoMet) effects on plasma homocysteine levels in healthy human subjects: a double-blind, placebo-controlled, randomized clinical trial

Michael A Thompson  1 , Brent A Bauer, Laura L Loehrer, Stephen S Cha, Jayawant N Mandrekar, Amit Sood, Dietlind L Wahner-Roedler
Affiliations
Randomized Controlled Trial

Dietary supplement S-adenosyl-L-methionine (AdoMet) effects on plasma homocysteine levels in healthy human subjects: a double-blind, placebo-controlled, randomized clinical trial

Michael A Thompson et al. J Altern Complement Med. 2009 May.

Abstract

Objectives: To determine if exogenous S-adenosyl-l-methionine (AdoMet), a commonly used nutritional supplement, increases the level of plasma homocysteine (Hcy), a potential cardiovascular risk factor, in healthy human subjects.

Design: Double-blind, placebo-controlled, randomized clinical trial.

Setting: Mayo Clinic, Rochester, Minnesota.

Subjects: Fifty-two (52) healthy human volunteers.

Intervention: Subjects received placebo or AdoMet (800 mg per day) for 4 weeks. Hcy levels were measured before and after administration of AdoMet or placebo.

Outcome measures: The primary outcome measure was change in Hcy level. Secondary outcome measures included an interim Hcy determination (at 2 weeks) and changes in levels of high-sensitivity C-reactive protein (hsCRP), lipids, and alanine aminotransferase.

Results: There was no statistically significant change in Hcy between groups. Similarly, no statistically significant differences in change in Hcy or hsCRP levels were observed at 2 or 4 weeks. There was a small but statistically significant increase (p < 0.04) in alanine aminotransferase at week 2 and a statistically significant decrease (p < 0.04) in total cholesterol in the AdoMet group compared with the placebo group.

Conclusions: AdoMet at a daily dose of 800 mg for 4 weeks does not appear to significantly affect Hcy levels in the blood.

Trial registration: ClinicalTrials.gov NCT00284011.

PubMed Disclaimer

Figures

FIG. 1. (A)
FIG. 1. (A)
The structure of S-adenosyl-l-methionine (AdoMet). (B) Homocysteine (Hcy) and homocystine. Hcy is a monomer, and homocystine is an Hcy dimer. (C) Metabolic pathways of AdoMet and Hcy. The circled numbers correspond to enzymatic reactions: 1, AdoMet decarboxylase; 2, AdoMet-dependent; MT, methyltransferase; 3, Gly-N-MT; 4, S-adenosyl-l-homocysteine (AdoHcy) hydrolase; 5, cystathione β-synthase; 6, betaine Hcy MT; 7, MTHF reductase; 8, AdoMet synthetase; 9, cystathione γ-lase. The AdoMet, AdoHcy, and Hcy pathway is emphasized in bold. ATP, adenosine triphosphate; Cys, cysteine; DMG, dimethyl-glycine; Gly, glycine; Met, methionine; MS, methyltetrahydrofolate-Hcy MT; MTHF, methyltetrahydrofolate; Pi, inorganic phosphate; PPi, inorganic diphosphate; PLP, pyridoxal phosphate; Sar, sarcosine; THF, tetrahydrofolate.
FIG. 2.
FIG. 2.
Flow diagram of clinical trial. AdoMet, S-adenosyl-l-methionine; ALT, alanine aminotransferase.
See this image and copyright information in PMC

References

    1. Balluz LS. Kieszak SM. Philen RM. Mulinare J. Vitamin and mineral supplement use in the United States: Results from the third National Health and Nutrition Examination Survey. Arch Fam Med. 2000;9:258–262. Erratum in Arch Fam Med 2000;9:652. - PubMed
    1. Ervin RB. Wright JD. Kennedy-Stephenson J. Use of dietary supplements in the United States, 1988–94. Vital Health Stat 11. 1999;244(i–iii):1–14. - PubMed
    1. Barnes PM. Powell-Griner E. McFann K. Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data. 2004;343:1–19. - PubMed
    1. Jacobsen S. Danneskiold-Samsøe B. Andersen RB. Oral S-adenosylmethionine in primary fibromyalgia: Double-blind clinical evaluation. Scand J Rheumatol. 1991;20:294–302. - PubMed
    1. S-Adenosyl-l-Methionine for Treatment of Depression, Osteoarthritis, and Liver Disease. Summary, Evidence Report/Technology Assessment: Number 64. Publication No. 02-E033. Rockville, MD: Agency for Healthcare Research and Quality; 2002.

Publication types

Associated data